Approval · Notice of Compliance 14025 · 2013
NAROPIN: Notice of Compliance 14025
Issued January 16, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14025
- Date
- January 16, 2013
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph. Update to the Action and Clinical Pharmacology Section
- Therapeutic class
- Local anaesthetic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAROPIN | Not yet assigned | — |
Medicinal ingredients
- ROPIVACAINE HYDROCHLORIDE 2 MG per ML
- ROPIVACAINE HYDROCHLORIDE 5 MG per ML
- ROPIVACAINE HYDROCHLORIDE 10 MG per ML